Eton Pharmaceuticals: chief business officer David Krempa sold 4,166 shares

What happened David Krempa, chief business officer, sold 4,166 shares in an open-market sale on Oct 6, 2026, at a weighted average price of $55.07 for $229,406. The filing also shows that Krempa exercised derivatives (options) for 10,522 shares on Oct 2, 2026.

Key details

• Transaction dates and prices: exercised options for 10,522 shares on Oct 2, 2026 (derivative exercise; one disposal line reports $0.00); sold 4,166 shares on Oct 6, 2026 at a weighted average price of $55.07 (sales ranged $54.915 to $55.135). (See footnotes F1, F2.)
• Proceeds: $229,406 reported for the Oct 6, 2026 sale.
• Shares owned after the transaction: not stated on the Form 4 provided.
• Relevant footnotes: F1—reporting person will provide full trade-by-trade pricing details on request; F2—sale prices ranged $54.915 to $55.135 and $55.07 is the weighted average; F3—report notes a prior grant of 42,088 restricted stock units on Oct 2, 2024 vesting in four equal annual installments beginning Oct 2, 2025.
• Filing timeliness: the Form 4 filed Oct 6, 2026 does not indicate a late filing.

Why it may matter

• The filing shows an exercise of derivatives (options) for 10,522 shares on Oct 2, 2026 and a separate open-market sale of 4,166 shares on Oct 6, 2026; the $0.00 disposal line for the derivative is reported on the Form 4.
• The Oct 6 sale was executed in multiple trades per the filing (see F2). A filing does not show why the insider traded or why the company acted.